Friedreich’s Ataxia | CHOP Research Institute

Friedreich’s Ataxia

NAD+ (nicotinamide adenine dinucleotide) is an important substance found in the body that plays a role in energy metabolism and overall health.
Published on
May 19, 2023
CHOP research paved the way for the first treatment for Friedreich’s ataxia (FA), an inherited neurodegenerative disease.
Published on
Mar 17, 2023
Learn about a first-of-its-kind FDA approval and a PCORI project that aims to turn evidence-based research into clinical practice more quickly.
Published on
Jul 8, 2022
This week’s In the News features ASGCT meeting highlights, our new Nephrology Chief, and more.

This is a multicenter natural history and clinical measure study.

Fostering the careers of the next generation of scientists who seek to discover causes and potential treatments for the class of disorders known as neurodevelopmental disabilities.

The Lynch Lab conducts clinical, translational, and basic science research on the rare disease Friedreich ataxia

Providing comprehensive care for patients with Friedreich’s Ataxia (FA), a rare, progressive neurogenetic condition, while advancing research to improve the lives of all individuals with FA.

Published on
Dec 18, 2020
This week’s In the News features firearms research, stillbirths during COVID, donations to the Friedreich’s Ataxia Center of Excellence, and postdocs highlighted for diversity.
Published on
Oct 9, 2020
In the News shares new findings on the treatment of COVID-19 complications, driving license suspensions, lymphatic disorders, and more.